Israeli Techsomed, who developed an image analysis system for cancer treatment, received $ 2.6 million in venture capital investment
Techsomed - an Israeli startup that developed BioTrace - the world's first and only ultrasound image analysis system for cancer treatment - received $ 2.6 million in venture capital investments.
The BioTrace monitoring system is installed in standard medical ultrasound machines to monitor the response of tissues to thermal ablation — the process of destroying tumors using intense heat or freezing. The system creates visual models of the effect on cancer tissues both during the operation and during the day after it.
Knowledgeable people say that during thermal ablation, the biggest problem was the impossibility of visualizing and controlling real tissue damage in real time.
Techsomed's patented artificial intelligence, on which the BioTrace monitoring system is based, allows surgeons not only to guess what happens to tumors during surgery, but to know for sure. See literally. And, as a result, to influence the affected areas more accurately, to remove all cancer cells, and thereby reduce the likelihood of recurrence.
')
Johnson & Johnson Innovation - JJDC, Inc. has already invested in a startup. SCREEN Holdings (Japan), AMIT-Technion (Alfred Mann Institute), NextLeap Ventures and another Japanese foundation - Axil Capital. By the way, here at Axil Capital, there is no doubt Techsomed’s big future. It is believed that the BioTrace system should become a new medical standard.
Techsomed intends to spend the money received from venture capital investors to open an office in Japan (for now there is only in Israel) and to obtain regulatory approvals in the United States, the European Union and Japan.
More news about Israeli startups in my tlgrm channel https://t.me/InvestToIsrael
The BioTrace monitoring system is installed in standard medical ultrasound machines to monitor the response of tissues to thermal ablation — the process of destroying tumors using intense heat or freezing. The system creates visual models of the effect on cancer tissues both during the operation and during the day after it.
Knowledgeable people say that during thermal ablation, the biggest problem was the impossibility of visualizing and controlling real tissue damage in real time.
Techsomed's patented artificial intelligence, on which the BioTrace monitoring system is based, allows surgeons not only to guess what happens to tumors during surgery, but to know for sure. See literally. And, as a result, to influence the affected areas more accurately, to remove all cancer cells, and thereby reduce the likelihood of recurrence.
')
Johnson & Johnson Innovation - JJDC, Inc. has already invested in a startup. SCREEN Holdings (Japan), AMIT-Technion (Alfred Mann Institute), NextLeap Ventures and another Japanese foundation - Axil Capital. By the way, here at Axil Capital, there is no doubt Techsomed’s big future. It is believed that the BioTrace system should become a new medical standard.
Techsomed intends to spend the money received from venture capital investors to open an office in Japan (for now there is only in Israel) and to obtain regulatory approvals in the United States, the European Union and Japan.
More news about Israeli startups in my tlgrm channel https://t.me/InvestToIsrael
Source: https://habr.com/ru/post/455014/
All Articles